A wide spectrum of biological functions, including cell growth, survival, proliferation, differentiation, adhesion, migration, and communication, critically depend on tyrosine phosphorylations that occur on both cell surface receptors and intracellular effectors. Phosphotyrosines (pY) interact specifically with Src-homology-2 (SH2) domains to regulate protein-protein interactions and protein conformations (Sadowski et al., 1986; Waksman et al., 1992).

Two sets of enzymes reciprocally control tyrosine phosphorylation: protein tyrosine kinases (PTKs) that catalyze tyrosine phosphorylation and protein tyrosine phosphatases (PTPases) that catalyze the removal of phosphates from pY residues (Denu and Dixon, 1998; Paul and Lombroso, 2003; Senis, 2013; Tonks, 2006). Whereas a subset of PTKs and PTPases are anchored to cell membranes (e.g., receptor tyrosine kinases and receptor-like PTPases), others are cytoplasmic that are recruited by membrane receptors in response to an environmental cue.

SHP1 (PTPN6) and its paralog SHP2 (PTPN11) are cytoplasmic PTPases that are crucial for a wide range of cellular functions. Their dysregulation, due to either mutations or aberrant expression, contributes to a number of human pathologies, particularly cancer (Bard-Chapeau et al., 2011). SHP099, an allosteric inhibitor of SHP2 (Chen et al., 2016), is being evaluated in multiple clinical trials for cancer. SHP1 and SHP2 are structurally similar, both contain tandem-SH2 domains followed by a catalytic domain, and are coexpressed in multiple cell types. However, they are not redundant and contribute to different aspects of cellular functions (Lorenz, 2009; Poole and Jones, 2005). The biochemical basis for these differences is unclear.

Among the many reported functions of SHP1 and SHP2, they are known as key effectors for numerous inhibitory immunoreceptors, which recruit SHP1 and/or SHP2 to repress phosphorylation-dependent stimulatory signaling. These receptors include PD-1, BTLA, and LAIR, which repress the functions of T and B lymphocytes; SIRPα, which inhibits phagocytosis of myeloid cells; KIR/Ly49, which prevent NK cells from killing self-cells; PECAM1 and G6b-B, which inhibit platelet functions (Coxon et al., 2017); as well as several members of Siglecs, Sialic-acid-recognizing receptors. Collectively, these receptors operate as ‘immune checkpoints’ essential for self-tolerance, but can also be subverted by cancers and viruses to escape immune destruction. PD-1 blockade antibodies have produced impressive clinical activity against a subset of human cancer. There is also substantial interest in targeting other inhibitory receptors, or SHP1/SHP2 to overcome resistance to PD-1 targeted therapy (Chen et al., 2020), with promising results in mouse tumor models.

Common to SHP1/SHP2-recruiting immunoreceptors is the presence of one or both types of pY-based motifs in their intracellular domains (ICD): immunoreceptor tyrosine-based inhibitory motif (ITIM, consensus sequence S/I/V/LxYxxI/V/L) (Burshtyn et al., 1996; Daëron et al., 1995) and immunoreceptor tyrosine-based switch motif (ITSM, consensus sequence TxYxxV/I) (Cannons et al., 2011). Once phosphorylated, ITIM and ITSM act as docking sites for the SH2 domains of SHP1/SHP2. Moreover, ITSM in some receptors interacts with SH2-containing adaptor proteins SH2D1A and SH2D1B (Cannons et al., 2011).

Despite the general presumption that ITIM/ITSM-containing receptors recruit both SHP1 and SHP2, increasing evidence suggests that these receptors exhibit differential phosphatase-binding specificities. For example, PD-1 strongly recruits SHP2, but not SHP1, in both T cells and B cells (Okazaki et al., 2001; Yokosuka et al., 2012). In contrast, BTLA prefers to recruit SHP1 over SHP2 (Celis-Gutierrez et al., 2019; Mintz et al., 2019; Xu et al., 2020). These binding preferences were consistent with the functional analyses: deletion of SHP2, but not of SHP1, markedly decreases the inhibitory function of PD-1 in T cells (Xu et al., 2020). In contrast, the inhibitory function of BTLA is severely reduced by SHP1 deletion but not SHP2 deletion from T cells (Xu et al., 2020). Notably, FcγIIRB, another ITIM-containing receptor, recruits neither SHP1 nor SHP2, but recruits and signals through the lipid phosphatase SHIP (Ono et al., 1997).

The distinct phosphatase preferences of PD-1, BTLA, and FcγIIRB are striking and puzzling given the similarities in their pY motifs and in the structures of SHP1/SHP2. This knowledge gap has made it difficult to predict the functions, redundancy, competition, or synergy of the many ITIM-bearing receptors. Addressing these questions has met several challenges. First, both SHP1 and SHP2 can potentially interact with dual phosphorylated receptors in multiple possible modes: monovalent, bivalent parallel, or bivalent antiparallel, etc. Second, there is no reported structure for dual phosphorylated PD-1 or BTLA interacting with SHP1 or SHP2. Third, binding assays using SH2 domains of SHP1/SHP2, as extensively used in previous studies, likely do not reflect the behaviors of full-length proteins in cells. This is because SHP1 and SHP2 undergo complex regulation due to intramolecular contacts (Hof et al., 1998; Pádua et al., 2018; Yang et al., 2003) and reportedly dephosphorylate their docking sites within the receptor (Goyette et al., 2017; Hui et al., 2017; Yokosuka et al., 2012).

In this study, we dissected the molecular mechanisms by which PD-1 and BTLA discriminate between SHP1 and SHP2. We measured the affinities of all potential pY:SH2 interactions involved in PD-1 and BTLA recruitment of SHP1 and SHP2 using surface plasmon resonance (SPR) and identified the optimal binding orientations of both SHP1 and SHP2. We then measured the recruitment of full-length SHP1 and SHP2 to PD-1 microclusters in intact, stimulated T cells expressing similar amounts of either wild-type (WT) or domain-swapped mutant of PD-1. This clean, ‘in-cell’ recruitment assay enabled us to quantitatively measure the net recruitment of SHP1/SHP2 after integrating the various regulatory mechanisms (autoinhibition, autodephosphorylation, etc.), as well as biophysical parameters (avidity, stoichiometry, compartmentalization, etc.). Through these experiments, we identified differing features between SHP1 and SHP2, and between PD-1 and BTLA, that led to the specificity dichotomy. Specifically, we isolated a single residue in ITIM that gates the SHP1-binding activity. Our work sheds light on the effector-binding specificities of a growing list of immune checkpoint receptors.

SHP1 and SHP2 are key regulators of cell survival, proliferation, differentiation, and migration (Gascoigne et al., 2015; Ke et al., 2007; Kuo et al., 2010; Lorenz, 2009; Paling and Welham, 2002). Coexpressed in hematopoietic cells, they operate as central effectors for inhibitory immunoreceptors that contain ITIM and ITSM. Dissecting the precise mechanism by which these receptors discriminate between SHP1 and SHP2 is required to predict and understand their ‘checkpoint’ functions. In the present work, we combined biophysical, biochemical, and cellular imaging approaches to investigate the specificity dichotomy of PD-1 and BTLA. Our data have revealed distinct properties between the SH2 domains of SHP1 and SHP2, and between the ITIMs of these two checkpoint receptors. We also report that the differential SHP1-binding activities of PD-1 and BTLA can be largely attributed to a single (pY+1) residue of their ITIMs: the polarity and size of this residue gate SHP1 recruitment in T cells.

In human genome, at least 32 receptors contain two or more ITIMs or ITSMs in tandem. Conceivably, the tandem pY motifs favor their bivalent interactions with tSH2 of SHP1 and SHP2. Mathematical modeling predicts that bivalent binding, even contributed by two weak bonds, can produce stable protein complexes due to an avidity effect and a reduction of off-rate of protein complexes (Diestler and Knapp, 2008). In support of this notion, an earlier study showed that mutation of either ITIM or ITSM of BTLA abolishes its association with both SHP1 and SHP2 (Watanabe et al., 2003), a result that we have confirmed in the present study (Figure 5B). The bivalent binding mode appears to be less strict in the case of PD-1 since its ITIM mutant retained the ability to co-IP SHP2 (Chemnitz et al., 2004; Okazaki et al., 2001; Patsoukis et al., 2020; Peled et al., 2018; Yokosuka et al., 2012). A recent study suggested that SHP2 may crosslink two PD-1 molecules at the ITSM (Patsoukis et al., 2020), whereas other studies indicate that PD-1-ITIM contributes to SHP2 recruitment and activation (Marasco et al., 2020; Peled et al., 2018; Yokosuka et al., 2012). In our hands, ITIM mutant recruited significantly less SHP2 than PD-1^WT in co-IP, microcluster enrichment, and single-molecule assays, supporting the involvement of ITIM, and the 1:1 bivalent mode as the dominant mode of PD-1:SHP2 interaction (Figure 2, Figure 3—figure supplement 1). In both BTLA and PD-1, the ITIM tyrosine and ITSM tyrosine are separated by 25 residues (Riley, 2009), and similar spacing are found in numerous ITIM/ITSM-containing receptors (Supplementary file 4). This conserved distance may allow for simultaneous engagement of the ITIM and ITSM by the tSH2 of SHP1/SHP2 in the 1:1 bivalent mode. The bivalent binding likely occurs in a sequential fashion, in which the higher-affinity intermolecular contact precedes and converts the low-affinity binding to a pseudo-intramolecular event, as supported by mathematical modeling (Zhou and Gilson, 2009).

Our SPR data revealed certain promiscuities in the binding of their SH2 to ITIM and ITSM (Figures 3 and 6). Theoretically, SHP1 and SHP2 may bind to PD-1 and BTLA in either a parallel or an antiparallel orientation. However, free energy calculations suggest parallel mode as the most stable form for both PD-1 and BTLA (Supplementary file 2), consistent with a recent study on PD-1:SHP2 interaction (Marasco et al., 2020) and an earlier study on SHP2 interaction with PECAM1 (Jackson et al., 1997). To our knowledge, all ITIM/ITSM receptors with the exception of SLAMF5 in human genome contain an ITIM N-terminal to ITSM (Supplementary file 4). This spatial arrangement might allow these receptors to bind SHP1 and SHP2 in the parallel mode. The physiological significance of parallel binding is unclear, but it might increase the molecular reach of the PTPase domain (Clemens et al., 2021; Zhang et al., 2019), or avoid potential steric clash with the plasma membrane.

Extensive genetic and biochemical evidence shows that SHP1 and SHP2 differ in their physiological functions. SHP2 reportedly acts as both a positive and negative regulator, whereas SHP1 is primarily known as a negative regulator in cell signaling (Lorenz, 2009; Poole and Jones, 2005). The biochemical basis of their functional divergence is unknown. The most striking difference between SHP1 and SHP2, based on the current study, are their cSH2 domains: while SHP2-cSH2 binds to PD-1-ITSM with a high affinity, SHP1-cSH2 exhibits weak binding to PD-1-ITSM (Figure 3A and B). This distinction accounts for the undetectable PD-1:SHP1 association in T cells (Xu et al., 2020; Yokosuka et al., 2012), supported by our domain-swapping experiments (Figure 4B and C). Thus, PD-1 prefers SHP2 over SHP1 primarily based upon the stability of ITSM:cSH2 interaction. We speculate, in a more general sense, that the differing cSH2 domains of SHP1 and SHP2 might enable their recruitment to distinct signalosomes, leading to distinct functional outcomes. Indeed, SHP1-cSH2 and SHP2-cSH2 exhibit 51.9% homology in amino acid identities, and based on a recent NMR structure (Marasco et al., 2020), several residues implicated in PD-1-ITSM:SHP2-cSH2 interactions are altered in SHP1-cSH2 (Figure 4A).

Given the very weak affinity of the SHP1-cSH2 domain with the ITSM of both PD-1 and BTLA, we propose that receptors that stably recruit SHP1 must contain a strong docking site for SHP1-nSH2, such as the BTLA-ITIM (Figure 6A and B). The PD-1-ITIM, however, might be too weak to support stable, bivalent PD-1:SHP1 binding. Moreover, because SHP1/SHP2 undergo autoinhibition due to intramolecular (cis) interactions between the nSH2 and the catalytic domain (Pádua et al., 2018; Pei et al., 1994; Yang et al., 2003), a stronger ITIM might also allow the receptor to more efficiently release the autoinhibition of SHP1/SHP2 in trans. This may also help explain the inability of SHP1 to compensate for PD-1 function in SHP2-deficient T cells (Figure 1C; Xu et al., 2020), even though in a subset of Jurkat cells, we were able to detect weak SHP1 enrichment to PD-1 microclusters.

Biochemical research on PD-1 has led to a consensus that ITSM is its primary docking site for SHP2 (Chemnitz et al., 2004; Okazaki et al., 2001; Patsoukis et al., 2020; Peled et al., 2018; Yokosuka et al., 2012). Along this line, the current study shows that PD-1 uses ITSM to prefer SHP2 over SHP1 (Figure 3A and B). Thus, ITSM is the ‘dominant hand’ of PD-1. In contrast, the ‘dominant hand’ of BTLA appears to be its ITIM. Our data show that ITIM of BTLA serves as the primary docking site for SHP1 and allows BTLA to discriminate between SHP1 and SHP2 (Figure 6A and B).

SH2 binding is contributed by both pY and its flanking residues (Kuriyan and Cowburn, 1997; Pawson, 1995). Alanine is conserved at pY+1 position in the ITIMs of numerous immunoreceptors (Figure 8—figure supplement 1B), suggesting its critical role in the physiological functions of these receptors. In this sense, human PD-1 is an interesting exception: its ITIM appears to be the only ITIM that has a glycine at pY+1 position (Figure 8—figure supplement 1B). Our study demonstrates that the pY+1 glycine inhibits SHP1 recruitment, and replacement of glycine to an alanine, valine, leucine, or isoleucine was sufficient to induce PD-1:SHP1 association in T cells, whereas a polar, charged, or bulky residue was significantly less efficient to promote SHP1 binding (Figures 8 and 9). These results suggest that a medium-sized nonpolar residue at pY+1 position is a defining feature of a SHP1-docking site, specifically its nSH2 domain. Consistent with this model, PECAM1, another receptor reported to strongly prefer SHP2 over SHP1 (Jackson et al., 1997; Sagawa et al., 1997), has a polar residue threonine at pY+1 of its ITIM.

How could a medium-sized hydrophobic residue at pY+1 contribute to SH2 binding? Our homology structural modeling reveals a hydrophobic pocket within SHP1-nSH2 that best coordinates a medium-sized nonpolar side chain from the pY+1 position of ITIM (Figure 9A and B). We speculate that similar hydrophobic contacts likely stabilize BTLA-ITIM:SHP1-nSH2 interactions. A glycine at pY+1, as occurs in human PD-1-ITIM, likely impairs such hydrophobic interactions due to its small size or its structural flexibility, whereas a bulky residue (phenylalanine or tryptophan) would inhibit the interaction due to a steric effect. Further structural studies will be needed to definitively test these notions.

All data generated or analysed during this study are included in the manuscript and supporting file.

1. 1. Ahrends T
   2. Spanjaard A
   3. Pilzecker B
   4. Bąbała N
   5. Bovens A
   6. Xiao Y
   7. Jacobs H
   8. Borst J

   (2017) CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness

   Immunity 47:848–861.

   https://doi.org/10.1016/j.immuni.2017.10.009

   • PubMed
   • Google Scholar
2. 1. Alvarez-Errico D
   2. Aguilar H
   3. Kitzig F
   4. Brckalo T
   5. Sayós J
   6. López-Botet M

   (2004) IREM-1 is a novel inhibitory receptor expressed by myeloid cells

   European Journal of Immunology 34:3690–3701.

   https://doi.org/10.1002/eji.200425433

   • PubMed
   • Google Scholar
3. 1. Avril T
   2. Floyd H
   3. Lopez F
   4. Vivier E
   5. Crocker PR

   (2004) The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells

   Journal of Immunology 173:6841–6849.

   https://doi.org/10.4049/jimmunol.173.11.6841

   • PubMed
   • Google Scholar
4. 1. Bard-Chapeau EA
   2. Li S
   3. Ding J
   4. Zhang SS
   5. Zhu HH
   6. Princen F
   7. Fang DD
   8. Han T
   9. Bailly-Maitre B
   10. Poli V
   11. Varki NM
   12. Wang H
   13. Feng GS

   (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis

   Cancer Cell 19:629–639.

   https://doi.org/10.1016/j.ccr.2011.03.023

   • PubMed
   • Google Scholar
5. 1. Burshtyn DN
   2. Scharenberg AM
   3. Wagtmann N
   4. Rajagopalan S
   5. Berrada K
   6. Yi T
   7. Kinet JP
   8. Long EO

   (1996) Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor

   Immunity 4:77–85.

   https://doi.org/10.1016/s1074-7613(00)80300-3

   • PubMed
   • Google Scholar
6. 1. Cannons JL
   2. Tangye SG
   3. Schwartzberg PL

   (2011) SLAM family receptors and SAP adaptors in immunity

   Annual Review of Immunology 29:665–705.

   https://doi.org/10.1146/annurev-immunol-030409-101302

   • PubMed
   • Google Scholar
7. 1. Celis-Gutierrez J
   2. Blattmann P
   3. Zhai Y
   4. Jarmuzynski N
   5. Ruminski K
   6. Grégoire C
   7. Ounoughene Y
   8. Fiore F
   9. Aebersold R
   10. Roncagalli R
   11. Gstaiger M
   12. Malissen B

   (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

   Cell Reports 27:3315–3330.

   https://doi.org/10.1016/j.celrep.2019.05.041

   • PubMed
   • Google Scholar
8. 1. Chandradoss SD
   2. Haagsma AC
   3. Lee YK
   4. Hwang JH
   5. Nam JM
   6. Joo C

   (2014) Surface passivation for single-molecule protein studies

   Journal of Visualized Experiments 1:50549.

   https://doi.org/10.3791/50549

   • PubMed
   • Google Scholar
9. 1. Chemnitz JM
   2. Parry RV
   3. Nichols KE
   4. June CH
   5. Riley JL

   (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

   Journal of Immunology 173:945–954.

   https://doi.org/10.4049/jimmunol.173.2.945

   • PubMed
   • Google Scholar
10. 1. Chen YNP
    2. LaMarche MJ
    3. Chan HM
    4. Fekkes P
    5. Garcia-Fortanet J
    6. Acker MG
    7. Antonakos B
    8. Chen CHT
    9. Chen Z
    10. Cooke VG
    11. Dobson JR
    12. Deng Z
    13. Fei F
    14. Firestone B
    15. Fodor M
    16. Fridrich C
    17. Gao H
    18. Grunenfelder D
    19. Hao HX
    20. Jacob J
    21. Ho S
    22. Hsiao K
    23. Kang ZB
    24. Karki R
    25. Kato M
    26. Larrow J
    27. La Bonte LR
    28. Lenoir F
    29. Liu G
    30. Liu S
    31. Majumdar D
    32. Meyer MJ
    33. Palermo M
    34. Perez L
    35. Pu M
    36. Price E
    37. Quinn C
    38. Shakya S
    39. Shultz MD
    40. Slisz J
    41. Venkatesan K
    42. Wang P
    43. Warmuth M
    44. Williams S
    45. Yang G
    46. Yuan J
    47. Zhang JH
    48. Zhu P
    49. Ramsey T
    50. Keen NJ
    51. Sellers WR
    52. Stams T
    53. Fortin PD

    (2016) Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

    Nature 535:148–152.

    https://doi.org/10.1038/nature18621

    • PubMed
    • Google Scholar
11. 1. Chen D
    2. Barsoumian HB
    3. Yang L
    4. Younes AI
    5. Verma V
    6. Hu Y
    7. Menon H
    8. Wasley M
    9. Masropour F
    10. Mosaffa S
    11. Ozgen T
    12. Klein K
    13. Cortez MA
    14. Welsh JW

    (2020) SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer

    Cancer Immunology Research 8:883–894.

    https://doi.org/10.1158/2326-6066.CIR-19-0744

    • PubMed
    • Google Scholar
12. 1. Clemens L
    2. Kutuzov M
    3. Bayer KV
    4. Goyette J
    5. Allard J
    6. Dushek O

    (2021) Determination of the molecular reach of the protein tyrosine phosphatase SHP-1

    Biophysical Journal 120:2054–2066.

    https://doi.org/10.1016/j.bpj.2021.03.019

    • PubMed
    • Google Scholar
13. 1. Coxon CH
    2. Geer MJ
    3. Senis YA

    (2017) ITIM receptors: more than just inhibitors of platelet activation

    Blood 129:3407–3418.

    https://doi.org/10.1182/blood-2016-12-720185

    • PubMed
    • Google Scholar
14. 1. Crocker PR
    2. Paulson JC
    3. Varki A

    (2007) Siglecs and their roles in the immune system

    Nature Reviews. Immunology 7:255–266.

    https://doi.org/10.1038/nri2056

    • PubMed
    • Google Scholar
15. 1. Daëron M
    2. Latour S
    3. Malbec O
    4. Espinosa E
    5. Pina P
    6. Pasmans S
    7. Fridman WH

    (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation

    Immunity 3:635–646.

    https://doi.org/10.1016/1074-7613(95)90134-5

    • PubMed
    • Google Scholar
16. 1. Denu JM
    2. Dixon JE

    (1998) Protein tyrosine phosphatases: mechanisms of catalysis and regulation

    Current Opinion in Chemical Biology 2:633–641.

    https://doi.org/10.1016/s1367-5931(98)80095-1

    • PubMed
    • Google Scholar
17. 1. Diestler DJ
    2. Knapp EW

    (2008) Statistical thermodynamics of the stability of multivalent ligand-receptor complexes

    Physical Review Letters 100:178101.

    https://doi.org/10.1103/PhysRevLett.100.178101

    • PubMed
    • Google Scholar
18. 1. Edelstein AD
    2. Tsuchida MA
    3. Amodaj N
    4. Pinkard H
    5. Vale RD
    6. Stuurman N

    (2014) Advanced methods of microscope control using μManager software

    Journal of Biological Methods 1:e10.

    https://doi.org/10.14440/jbm.2014.36

    • PubMed
    • Google Scholar
19. 1. Gascoigne N
    2. Brzostek J
    3. Mehta M
    4. Zhao X
    5. Fu G
    6. Paster W
    7. Acuto O
    8. Rybakin V

    (2015)

    Themis and the control of SHP1 phosphatase activity in TCR signal strength during thymocyte positive selection

    Journal of Immunology 194:51.4.

    • Google Scholar
20. 1. Gavrieli M
    2. Watanabe N
    3. Loftin SK
    4. Murphy TL
    5. Murphy KM

    (2003) Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2

    Biochemical and Biophysical Research Communications 312:1236–1243.

    https://doi.org/10.1016/j.bbrc.2003.11.070

    • PubMed
    • Google Scholar
21. 1. Goyette J
    2. Salas CS
    3. Coker-Gordon N
    4. Bridge M
    5. Isaacson SA
    6. Allard J
    7. Dushek O

    (2017) Biophysical assay for tethered signaling reactions reveals tether-controlled activity for the phosphatase SHP-1

    Science Advances 3:e1601692.

    https://doi.org/10.1126/sciadv.1601692

    • PubMed
    • Google Scholar
22. 1. Hof P
    2. Pluskey S
    3. Dhe-Paganon S
    4. Eck MJ
    5. Shoelson SE

    (1998) Crystal structure of the tyrosine phosphatase SHP-2

    Cell 92:441–450.

    https://doi.org/10.1016/s0092-8674(00)80938-1

    • PubMed
    • Google Scholar
23. 1. Hui E
    2. Cheung J
    3. Zhu J
    4. Su X
    5. Taylor MJ
    6. Wallweber HA
    7. Sasmal DK
    8. Huang J
    9. Kim JM
    10. Mellman I
    11. Vale RD

    (2017) T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition

    Science 355:1428–1433.

    https://doi.org/10.1126/science.aaf1292

    • PubMed
    • Google Scholar
24. 1. Jackson DE
    2. Kupcho KR
    3. Newman PJ

    (1997) Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of platelet/endothelial cell adhesion molecule-1 (PECAM-1) that are required for the cellular association and activation of the protein-tyrosine phosphatase, SHP-2

    The Journal of Biological Chemistry 272:24868–24875.

    https://doi.org/10.1074/jbc.272.40.24868

    • PubMed
    • Google Scholar
25. 1. Ke Y
    2. Zhang EE
    3. Hagihara K
    4. Wu D
    5. Pang Y
    6. Klein R
    7. Curran T
    8. Ranscht B
    9. Feng GS

    (2007) Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality

    Molecular and Cellular Biology 27:6706–6717.

    https://doi.org/10.1128/MCB.01225-07

    • PubMed
    • Google Scholar
26. 1. Kuo E
    2. Park DK
    3. Tzvetanova ID
    4. Leiton CV
    5. Cho BS
    6. Colognato H

    (2010) Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development

    Journal of Neurochemistry 113:200–212.

    https://doi.org/10.1111/j.1471-4159.2010.06596.x

    • PubMed
    • Google Scholar
27. 1. Kuriyan J
    2. Cowburn D

    (1997) Modular peptide recognition domains in eukaryotic signaling

    Annual Review of Biophysics and Biomolecular Structure 26:259–288.

    https://doi.org/10.1146/annurev.biophys.26.1.259

    • PubMed
    • Google Scholar
28. 1. Lorenz U

    (2009) SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels

    Immunological Reviews 228:342–359.

    https://doi.org/10.1111/j.1600-065X.2008.00760.x

    • PubMed
    • Google Scholar
29. 1. Marasco M
    2. Berteotti A
    3. Weyershaeuser J
    4. Thorausch N
    5. Sikorska J
    6. Krausze J
    7. Brandt HJ
    8. Kirkpatrick J
    9. Rios P
    10. Schamel WW
    11. Köhn M
    12. Carlomagno T

    (2020) Molecular mechanism of SHP2 activation by PD-1 stimulation

    Science Advances 6:eaay4458.

    https://doi.org/10.1126/sciadv.aay4458

    • PubMed
    • Google Scholar
30. Software

    1. Masubuchi T

    (2021) Xu-and-Masubuchi-et-al-eLife-2021

    Github.

    https://github.com/HuiLabUCSD/Xu-and-Masubuchi-et-al-eLife-2021
31. 1. Mintz MA
    2. Felce JH
    3. Chou MY
    4. Mayya V
    5. Xu Y
    6. Shui JW
    7. An J
    8. Li Z
    9. Marson A
    10. Okada T
    11. Ware CF
    12. Kronenberg M
    13. Dustin ML
    14. Cyster JG

    (2019) The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis

    Immunity 51:310–323.

    https://doi.org/10.1016/j.immuni.2019.05.022

    • PubMed
    • Google Scholar
32. 1. Okazaki T
    2. Maeda A
    3. Nishimura H
    4. Kurosaki T
    5. Honjo T

    (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

    PNAS 98:13866–13871.

    https://doi.org/10.1073/pnas.231486598

    • PubMed
    • Google Scholar
33. 1. Ono M
    2. Okada H
    3. Bolland S
    4. Yanagi S
    5. Kurosaki T
    6. Ravetch JV

    (1997) Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling

    Cell 90:293–301.

    https://doi.org/10.1016/s0092-8674(00)80337-2

    • PubMed
    • Google Scholar
34. 1. Ovesný M
    2. Křížek P
    3. Borkovec J
    4. Svindrych Z
    5. Hagen GM

    (2014) ThunderSTORM: a comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging

    Bioinformatics 30:2389–2390.

    https://doi.org/10.1093/bioinformatics/btu202

    • PubMed
    • Google Scholar
35. 1. Pádua RAP
    2. Sun Y
    3. Marko I
    4. Pitsawong W
    5. Stiller JB
    6. Otten R
    7. Kern D

    (2018) Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

    Nature Communications 9:4507.

    https://doi.org/10.1038/s41467-018-06814-w

    • PubMed
    • Google Scholar
36. 1. Paling NRD
    2. Welham MJ

    (2002) Role of the protein tyrosine phosphatase SHP-1 (Src homology phosphatase-1) in the regulation of interleukin-3-induced survival, proliferation and signalling

    The Biochemical Journal 368:885–894.

    https://doi.org/10.1042/bj20021054

    • PubMed
    • Google Scholar
37. 1. Patsoukis N
    2. Duke-Cohan JS
    3. Chaudhri A
    4. Aksoylar HI
    5. Wang Q
    6. Council A
    7. Berg A
    8. Freeman GJ
    9. Boussiotis VA

    (2020) Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation

    Communications Biology 3:128.

    https://doi.org/10.1038/s42003-020-0845-0

    • PubMed
    • Google Scholar
38. 1. Paul S
    2. Lombroso PJ

    (2003) Receptor and nonreceptor protein tyrosine phosphatases in the nervous system

    Cellular and Molecular Life Sciences 60:2465–2482.

    https://doi.org/10.1007/s00018-003-3123-7

    • PubMed
    • Google Scholar
39. 1. Pawson T

    (1995) Protein modules and signalling networks

    Nature 373:573–580.

    https://doi.org/10.1038/373573a0

    • PubMed
    • Google Scholar
40. 1. Pei D
    2. Lorenz U
    3. Klingmüller U
    4. Neel BG
    5. Walsh CT

    (1994) Intramolecular regulation of protein tyrosine phosphatase SH-PTP1: a new function for Src homology 2 domains

    Biochemistry 33:15483–15493.

    https://doi.org/10.1021/bi00255a030

    • PubMed
    • Google Scholar
41. 1. Peled M
    2. Tocheva AS
    3. Sandigursky S
    4. Nayak S
    5. Philips EA
    6. Nichols KE
    7. Strazza M
    8. Azoulay-Alfaguter I
    9. Askenazi M
    10. Neel BG
    11. Pelzek AJ
    12. Ueberheide B
    13. Mor A

    (2018) Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor

    PNAS 115:E468–E477.

    https://doi.org/10.1073/pnas.1710437115

    • PubMed
    • Google Scholar
42. 1. Poole AW
    2. Jones ML

    (2005) A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail

    Cellular Signalling 17:1323–1332.

    https://doi.org/10.1016/j.cellsig.2005.05.016

    • PubMed
    • Google Scholar
43. 1. Riley JL

    (2009) PD-1 signaling in primary T cells

    Immunological Reviews 229:114–125.

    https://doi.org/10.1111/j.1600-065X.2009.00767.x

    • PubMed
    • Google Scholar
44. 1. Sadowski I
    2. Stone JC
    3. Pawson T

    (1986) A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps

    Molecular and Cellular Biology 6:4396–4408.

    https://doi.org/10.1128/mcb.6.12.4396-4408.1986

    • PubMed
    • Google Scholar
45. 1. Sagawa K
    2. Kimura T
    3. Swieter M
    4. Siraganian RP

    (1997) The protein-tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule PECAM-1 (CD31)

    The Journal of Biological Chemistry 272:31086–31091.

    https://doi.org/10.1074/jbc.272.49.31086

    • PubMed
    • Google Scholar
46. 1. Schindelin J
    2. Arganda-Carreras I
    3. Frise E
    4. Kaynig V
    5. Longair M
    6. Pietzsch T
    7. Preibisch S
    8. Rueden C
    9. Saalfeld S
    10. Schmid B
    11. Tinevez JY
    12. White DJ
    13. Hartenstein V
    14. Eliceiri K
    15. Tomancak P
    16. Cardona A

    (2012) Fiji: an open-source platform for biological-image analysis

    Nature Methods 9:676–682.

    https://doi.org/10.1038/nmeth.2019

    • PubMed
    • Google Scholar
47. 1. Senis YA

    (2013) Protein-tyrosine phosphatases: a new frontier in platelet signal transduction

    Journal of Thrombosis and Haemostasis 11:1800–1813.

    https://doi.org/10.1111/jth.12359

    • PubMed
    • Google Scholar
48. 1. Sui L
    2. Li N
    3. Liu Q
    4. Zhang W
    5. Wan T
    6. Wang B
    7. Luo K
    8. Sun H
    9. Cao X

    (2004) IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes

    Biochemical and Biophysical Research Communications 319:920–928.

    https://doi.org/10.1016/j.bbrc.2004.05.065

    • PubMed
    • Google Scholar
49. 1. Tonks NK

    (2006) Protein tyrosine phosphatases: from genes, to function, to disease

    Nature Reviews. Molecular Cell Biology 7:833–846.

    https://doi.org/10.1038/nrm2039

    • PubMed
    • Google Scholar
50. 1. Veillette A
    2. Thibaudeau E
    3. Latour S

    (1998) High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages

    The Journal of Biological Chemistry 273:22719–22728.

    https://doi.org/10.1074/jbc.273.35.22719

    • PubMed
    • Google Scholar
51. 1. Waksman G
    2. Kominos D
    3. Robertson SC
    4. Pant N
    5. Baltimore D
    6. Birge RB
    7. Cowburn D
    8. Hanafusa H
    9. Mayer BJ
    10. Overduin M
    11. Resh MD
    12. Rios CB
    13. Silverman L
    14. Kuriyan J

    (1992) Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides

    Nature 358:646–653.

    https://doi.org/10.1038/358646a0

    • PubMed
    • Google Scholar
52. 1. Watanabe N
    2. Gavrieli M
    3. Sedy JR
    4. Yang J
    5. Fallarino F
    6. Loftin SK
    7. Hurchla MA
    8. Zimmerman N
    9. Sim J
    10. Zang X
    11. Murphy TL
    12. Russell JH
    13. Allison JP
    14. Murphy KM

    (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

    Nature Immunology 4:670–679.

    https://doi.org/10.1038/ni944

    • PubMed
    • Google Scholar
53. 1. Waterhouse A
    2. Bertoni M
    3. Bienert S
    4. Studer G
    5. Tauriello G
    6. Gumienny R
    7. Heer FT
    8. de Beer TAP
    9. Rempfer C
    10. Bordoli L
    11. Lepore R
    12. Schwede T

    (2018) SWISS-MODEL: homology modelling of protein structures and complexes

    Nucleic Acids Research 46:W296–W303.

    https://doi.org/10.1093/nar/gky427

    • PubMed
    • Google Scholar
54. 1. Xu X
    2. Hou B
    3. Fulzele A
    4. Masubuchi T
    5. Zhao Y
    6. Wu Z
    7. Hu Y
    8. Jiang Y
    9. Ma Y
    10. Wang H
    11. Bennett EJ
    12. Fu G
    13. Hui E

    (2020) PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

    The Journal of Cell Biology 219:e201905085.

    https://doi.org/10.1083/jcb.201905085

    • PubMed
    • Google Scholar
55. 1. Yang J
    2. Liu L
    3. He D
    4. Song X
    5. Liang X
    6. Zhao ZJ
    7. Zhou GW

    (2003) Crystal structure of human protein-tyrosine phosphatase SHP-1

    The Journal of Biological Chemistry 278:6516–6520.

    https://doi.org/10.1074/jbc.M210430200

    • PubMed
    • Google Scholar
56. 1. Yokosuka T
    2. Takamatsu M
    3. Kobayashi-Imanishi W
    4. Hashimoto-Tane A
    5. Azuma M
    6. Saito T

    (2012) Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

    The Journal of Experimental Medicine 209:1201–1217.

    https://doi.org/10.1084/jem.20112741

    • PubMed
    • Google Scholar
57. 1. Zhang Y
    2. Clemens L
    3. Goyette J
    4. Allard J
    5. Dushek O
    6. Isaacson SA

    (2019) The Influence of Molecular Reach and Diffusivity on the Efficacy of Membrane-Confined Reactions

    Biophysical Journal 117:1189–1201.

    https://doi.org/10.1016/j.bpj.2019.08.023

    • PubMed
    • Google Scholar
58. 1. Zhou HX
    2. Gilson MK

    (2009) Theory of free energy and entropy in noncovalent binding

    Chemical Reviews 109:4092–4107.

    https://doi.org/10.1021/cr800551w

    • PubMed
    • Google Scholar

[Editors' note: this paper was reviewed by Review Commons.]

Reviewer #1 (Evidence, reproducibility and clarity (Required)):

This paper explores an interesting problem of SHP1/SHP2 preferences of inhibitory immunoreceptors. The author are quick to point out that many of their individual data points confirm published results at some level, but the power of the paper is in the parallel analysis of both PD1, which is strongly biased towards SHP2 and BTLA, which is biased towards SHP1. This gives them the opportunity to test the predictions of descriptive experiment by making simple mutated receptors with swapped ITIM or ITSM domains.

The work is very well done and generally the authors are quite careful and precise about the language used to describe results, in general.

The results are quite striking in that the find plenty of evidence for transient interaction of SHP1 with PD1 based on the biophysical measurements, but don't detect the interactions in pull down or in "in cell" microcluster recruitment experiments. In describing the pull-downs they discuss the issue of dissociation during washing potentially missing interactions that are taking place. I would prefer that the pull down is fine evidence for binding, but lack of pull down is not evidence for lack of binding. They should double check that this language is consistent. Also, unless something has changed in the microcluster binding experiments, this in situ recruitment of SHP2 to PD1 is only observed or a 2-3 minutes and then can't be detected, the situation for SHP2 becoming the same as it is for SHP1. If the kinetics are different in the cleaner systems that have now developed they should show this in a primary figure as this would be then different when what is reported previously.

We agree with the reviewer that pull down is evidence for binding. Indeed, in most, if not all of our assays, our results with pull down were consistent with those in the microcluster imaging. It does seem though the differences observed in the “in cell” microcluster recruitment experiments are less striking than in the pull down experiments. As suggested by the reviewer, we have checked through the manuscript and ensure the language is accurate and consistent.

In our recent study (PMID: 32437509), we conducted a side-by-side comparison of SHP2 and SHP1 recruitment kinetics to PD-1 in a similar system. Both microcluster imaging and co-IP assays showed that PD-1:SHP2 association lasted at least 10 minutes, whereas PD-1:SHP1 recruitment was nearly undetectable. The duration of PD-1:SHP2 association was in good agreement with Takashi Saito’s finding in CD4⁺ mouse primary T cells (PMID: 22641383). Regardless the somewhat different kinetics in different studies, SHP2 recruitment was transient, as pointed out by the reviewer. We believe that some other effectors contribute to PD-1 inhibitory signaling. In supportive of this notion, we recently found that PD-1 remains partially inhibitory in CD8⁺ T cells deficient in both SHP1 and SHP2 (PMID: 32437509).

The gap in this study is lack of any functional analysis. The Jurkat model could be quite useful as they have a relatively clean system for asking if the transient binding of SHP1 to PD1 has any functional impact, which they have not yet followed through on. Does PD-1 recruited SHP2 have any impact on function after the 5 minutes? Furthermore, the authors need to keep in mind that mice deficient in SHP2 respond to anti-PD1 checkpoint therapies (Rota, G., Niogret, C., Dang, A. T., Barros, C. R., Fonta, N. P., Alfei, F., Morgado, L., Zehn, D., Birchmeier, W., Vivier, E., and Guarda, G. (2018). Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling in vivo. Cell Rep, 23(1), 39-49. https://doi.org/10.1016/j.celrep.2018.03.026). This is an important issue to discuss in light the very interesting binding analysis the authors have performed. But I think the functional analysis can be part of a future paper.

We appreciate the reviewer’s comments and suggestions. To address the concern on the functional relevance, we first tested the magnitude of PD-1 mediated IL-2 inhibition in WT, SHP1 KO, SHP2 KO and SHP1/SHP2 double KO Jurkat cells using pembrolizumab, an FDAapproved PD-1 blockade antibody, to titrate PD-1 signaling. This new experiment revealed that deletion of SHP1 from Jurkat cells had little effect on PD-1 mediated suppression of IL-2. In contrast, deletion of SHP2 from Jurkat cells significantly decreased the PD-1 inhibitory effect. These results strongly suggest that the transient binding of SHP1 to PD1 does not contribute significantly to PD-1 signaling. We now show this new data as Figure 1C of the revised manuscript.

Relative IL-2 levels produced by PD-1+ WT, SHP1 KO, SHP2 KO or SHP1/2 DKO Jurkat cells stimulated with PD-L1+ Raji cells in the presence of increasing concentrations of pembrolizumab (0, 0.4, 1.3, 4.4, 13.3, 44, 133, or 267 nM). For each type of Jurkat cells, IL-2 data was normalized to that at the highest pembrolizumab concentration (267 nM, or 40 μg/ml). Error bars are s.d. from three independent experiments. ****P < 0.0001; ns, not significant; two-way ANOVA test.

Moreover, we conducted another functional assay to test whether SHP1 recruitment, induced by mutations at the PD-1-ITIM pY+1 residue, correlates with the abilities of PD-1 mutants to suppress IL-2 production. Through careful titration of lentivirus titer, we were able to establish seven Jurkat cell lines, each expressing similar levels of a PD-1 variant, with a different nonpolar residues at the pY+1 position of ITIM (see Figure S1H). After stimulating these cell lines side-by-side with PD-L1+ Raji B cells, we found a strong correlation between the degree of SHP1 recruitment and the degree of IL2 suppression, see Figure 9E of the revised manuscript. Therefore, our new functional data demonstrate that the pY+1 residue of ITIM gates SHP1 recruitment, but also influence PD-1 inhibitory function.

We also agree with this reviewer that our manuscript would benefit from discussion of functional analysis. To this end, we have rewritten both the introduction and Discussion section extensively to discuss more on the physiological and functional relevance.

Speaking of the SHP1/SHP2 recruitment kinetics, as the reviewer alluded to, we did observe SHP2 dissociation from PD-1 after 10 minutes, as seen by Saito and colleagues (PMID: 22641383), as well as our recent study (PMID: 32437509). On the other hand, there is also clear evidence that SHP2 is required for long term inhibitory effect of PD-1. For example, when we deleted SHP2 from Jurkat cells, the ability of PD-1 to suppress IL-2 production at 6-hour time point was decreased by >50%, see Figure 1C of the revised manuscript. We observed a similar effect at even 24 hours (data not shown). These data demonstrate the importance of SHP2 for sustained PD-1 mediated inhibition, even though the PD-1:SHP2 interaction is transient. It is likely that a transient interaction at the receptor level can translate to longer term downstream effects, perhaps by modulating the SHP2 activity. Notably, similar transient interactions have also been reported for TCR and ZAP70 (PMIDs: 12356870, 27869819).

We agree that the SHP2 KO phenotype reported by Rota et al. is interesting, and suggested that Shp2 is not the sole effector for PD-1 inhibitory function in vivo. Consistent with this notion, our recent cell-based study (PMID: 32437509) also suggested the existence of SHP2-independent function of PD-1. However, while it is straightforward to assume that SHP1 mediates the SHP2-independent function of PD-1, our functional experiments using SHP1 KO and SHP1/2 double KO T cells did not support this view (see Figure 1C of the revised manuscript). These results suggest that the SHP2-independent function of PD-1 is mediated by yet-to-be identified effectors. Nevertheless, the existence of SHP2-independent functions of PD-1 does not argue against the contribution of SHP2 in the PD-1 pathway, as has been demonstrated by a number of independent studies.

I would suggest that the title be modified slightly from "SHP1/SHP2 discrimination" to "differential SHP1/SHP2 interaction" and leave discussion of discrimination until they have the functional data integrated over times that are relevant to T cell transcriptional regulation (1-2 hrs). The functional analysis can be in another paper, but it would be interesting to have a paragraph in the discussion raising the outstanding issues beyond stable binding detected by the pull-down and microcluster recruitment experiments- what are the implications for function. Could the transient interactions in the noise of the steady state and equilibrium measurements be functional?

We thank the reviewer for the suggestion. We have changed the title to “Molecular Features Underlying Differential SHP1/SHP2 Binding of Immune Checkpoint Receptors”.

With regards to the discussion whether transient interactions in the noise of the steady state can be functional, it does not seem to be the case for PD-1:SHP1 interactions, as supported by the SHP1 and SHP2 KO experiments in this study and our previous study (PMID: 32437509). From a biochemistry perspective, we feel that even SHP1 is weakly recruited by PD-1, as we observed in a subset of cells, the ‘crappy’ ITIM would not be able to efficiently release the autoinhibition of SHP1. We now add these considerations in the Discussion section of the revised manuscript (lines 397-400).

I would summarise that the work is outstanding as biochemistry and biophysics and it should be published nearly as is. I'm suggesting minor revisions in that the changes are just to text, but I think this is important and somewhat nuanced aspect of the paper that will make it even more helpful to readers.

We appreciate the positive and insightful comments! We have revised the manuscript carefully according to this reviewer’s suggestion.

Reviewer #1 (Significance (Required)):

The authors generate a detailed descriptive data set about the component interaction of SHP1 and SHP2 SH2 domains with PD1 and BTLA intracellular domains. They then test hypotheses generated from the descriptive data set to better define the nature of the interactions and why PD1 recruits primarily SHP2, while BTLA mainly recruits SHP1. PD1 is a major driver or the cancer immunotherapy revolution and SHP2 is the major candidate for a signalling effector of PD1. This paper can become the reference paper for the specificity and engineering of this interaction, which will make it highly significant in a very active and still expanding field.

Referee Cross-commenting

I still feel that "discrimination" has a functional/activity connotation that is not addressed at all in this paper, but can be addressed. I'm happy to have the suggestion stand and let the authors decide. They need to live with it once its published. Another suggestion- the citations on regulation are mostly old. A good recent paper is Padua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., and Kern, D. (2018). Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nature Communications, 9(1), 4507. https://doi.org/10.1038/s41467-018-06814-w .

We have changed the title to as the reviewer suggested. We believe that the functional questions raised by this reviewer, including the SHP1 and SHP2 contribution in PD-1 signaling, had been addressed in our current study and our recent publication (PMID: 32437509). By measuring a pembrolizumab dose response in WT, SHP1 KO, SHP2 KO, and double KO T cells, we provided evidence that PD-1 inhibitory function is contributed by SHP2, but very little if any by SHP1 (see Figure 1C of the revised manuscript).

We thank this reviewer for suggesting the excellent reference. We have cited this reference in the revised manuscript (lines 86 and 396).

Reviewer #2 (Evidence, reproducibility and clarity (Required)):

In this study, Xu and co-workers investigate the biophysical nature of the interaction between the structurally-related non-transmembrane PTPs Shp1 and Shp2 with the ITIM/ITSMcontaining inhibitory receptors PD-1 and BTLA using cell-based, biochemical, biophysical and domain swapping assays. The primary aim being to better understand how these receptors discriminate between binding Shp1 and/or Shp2, and the orientation of Shp1 and Shp2 engagement. These are major unresolved questions in the field that the authors go some way to addressing in a methodical, rigorous, clear and concise manner. Findings are convincing, correlate well with previous findings and internally, and are complemented with excellent schematics, making it easy to comprehend.

Major comments

The authors focus primarily on binding affinities to explain differential binding of Shp1 and Shp2 by PD-1 and BTLA ITIMs and ITSMs, but this is only part of the story. Avidity, compartmentalization, stoichiometry of kinases, and relative abundance of Shp1 and Shp2 are also important aspects of the discriminatory mechanism that are not addressed. Competition assays would go some way to addressing the latter point and should at least be considered and discussed.

We agree that various parameters mentioned by this reviewer, such as compartmentalization and relative expression levels would be a concern for a purely cell-free system such as the SPR experiments (Figures 3 and 6), however, we feel that our cell-based assays (Figure 4B and Figures 7-9), already integrate these parameters. This is also precisely the reason why we chose to examine the recruitments of SHP1/2 in a cellular context in conjunction with cell-free systems.

Regarding the competition, we have observed generally consistent results in both WT and SHP2 KO background, with or without the potential competition from endogenous SHP2 (Figure 7B and Figure S4). Our data suggests that competition is not a dominant mechanism for the recruitment specificity we observed.

In the revised manuscript, we have clarified these points in lines 93-96.

Similarly, authors do not address how distortion of the pY binding pocket of Shp1 and Shp2 nSH2 domains in the auto-inhibited conformation is released, allowing the domain to engage with phopho-ITIM/ITSM. Again, this should at least be discussed. Current binding studies do not address this issue.

We feel that the overall recruitment to the PD-1 microclusters as we observed in cells already integrate this auto-inhibition mechanism of SHP1 and SHP2, because we used full length proteins. We do agree with the reviewer that future studies are warranted to address the contributions of each mechanism, including auto-inhibition, concentration, competition, etc., to the overall recruitment. This might require careful and extensive biophysical analyses coupled with mathematical modeling given the complex regulation of SHP1 and SHP2. As suggested by this reviewer, we have discussed the autoinhibition mechanism in multiple locations of the revised manuscript, e.g. lines 95, 395, 397.

Minor comments:

Phosphorylation should be indicated in schematic representations in Figures 3, 6 b, c.

We thank the reviewer for this advice, we have now indicated phosphorylation in the revised figure 3 and 6.

Cellular and physiological significance should be further discussed, as well as broader implications of findings to other ITIM/ITSM-containing receptors in other lineages.

We agree with the reviewer that ITIM/ITSM-containing receptors have a much broader implication. As suggested, we have revised the introduction section extensively to put the work in a broader context. For example, we now mention the functions of these receptors in various cell types, including T cells, B cells, NK cells, platelets and cells of the myeloid lineage.

Reviewer #2 (Significance (Required)):

Findings from this study advance our knowledge of how inhibitory checkpoint regulatory receptors discriminate between Shp1 and Shp2, which has important implications for understanding how the unique biochemical, cellular and physiological functions of these receptors and phosphatases are dictated. Indeed, findings lay the foundation for a universal mechanism, that may apply to all ITIM/ITSM receptors in other cell lineages, and perhaps novel ways of targeting these interactions therapeutically.

Compare to existing published knowledge

Although largely correlative with previous studies, findings from this study start to fill major gaps in our knowledge of these biochemical processes, in a highly rigorous, concise and clear manner. Findings from previous studies were more 'piecemeal', whereas this study consolidates and advances important nuances of these interactions. Moreover, it lays the foundation for further structural, physiological and therapeutic studies.

Audience

The immune receptor signaling community and beyond, including any lineage in which ITIM/ITSM-containing receptors play a major role in regulating cellular responses.

Your expertise

ITIM/ITSM-containing receptors, kinase-phosphatase molecular switches, cellular reactivity to extracellular matrix proteins

Referee Cross-commenting

Generally agree with reviewer's comments. Constructive overall and fair. Although I was thinking additional competition experiments, I do not think necessary. Over the top for this study. Hence, 1 month should suffice to revise accordingly.

We thank this reviewer for the constructive and fair comments!

Reviewer #3 (Evidence, reproducibility and clarity (Required)):

Summary:

Inhibitory immune receptors containing ITIMs function through recruiting the phosphatases SHP-1 and SHP-2. SHP-1 and SHP-2 are remarkably similar yet have different roles in vivo.

How can ITIM-containing immune receptors specifically recruit SHP-1 or SHP-2? In this paper, Xu et al. ask how SHP-1 vs SHP-2 specificity is achieved. They use very thorough biochemical assays to measure the affinity of SHP-1 and SHP-2 for various ITIM/ITSMs and finally pin point some key amino acids that switch an ITIM/ITSM from SHP-2 to SHP-1 specificity. The in vitro biochemical assays are augmented by in cell assays that support their conclusions. Overall, this paper is an incredibly elegant and straight forward paper addressing how SHP-1/SHP-2 specificity is achieved.

Major Comments:

None.

Minor Comments:

Could the western blots in Figure 1 be quantified as the western blots in other figures?

We have quantified the blots in Figure 1 as suggested in the revised manuscript.

The data that the y+1 reside is essential for SHP-1/2 specificity is very convincing. We are curious if the other residues of the ITIM/ITSM also contribute to this specificity, albeit less potently. The PD-1 G224A mutant is still less potent than the PD-1 BTLA ITIM swap, suggesting that while the y+1 position is most important, the other residues contribute some specificity. The authors also included data on a PD-1 variant with the BTLA ITIM A224G mutation (8f), which is slightly better at recruiting SHP-1 than the PD-1 ITIM. It may be worth mentioning this data in the text of the paper as well as displaying it in the figure.

The reviewer raised an excellent point, yes, our data does suggest that other pY-flanking residues within the ITIM also contribute to SHP1 binding. However, the pY+1 residue replacement produced the strongest effect as the reviewer noted. In the revised manuscript, we have acknowledged the potential contributions of other residues.

To further clarify this point, we performed a structural homology modeling of PD-1-pITIM:SHP1nSH2 complex based on the published crystal structure of PD-1-pITIM:SHP2-nSH2 (PDB code: 6ROY) (PMID: 32064351). The simulated structure identified a hydrophobic pocket within SHP1-nSH2 that appeared to bind nonpolar side chain at the pY+1 position. Moreover, the size of the pocket explains why a medium-sized residue would fit the best. These provide a structural interpretation for the important role of the Y+1 position. We now showed the data as Figure 9A, B in the revised manuscript.

A brief introduction to ITIM vs ITSM in the introduction of the paper may be helpful background for readers. For example, ITIM receptors are reasonably well known but how ITSM functionally differs is probably less well known.

We have rewritten the introduction about ITIM and ITSM for better clarity. Specifically, we now mention that some ITSM interacts with both SHP1/2 and SH2-containing adaptor proteins.

Although not the major focus of the paper, broadening out this SHP-1/2 specificity to other immune receptors in the discussion is fascinating. (a) The authors find that a Valine, Leucine, or Isoleucine in place of the Alanine in y+1 is very close to equivalent, yet the A is highly conserved. The authors speculate that there may be an advantage to sub-maximal SHP-1 affinity because it is more easy to regulate. I think this is reasonable speculation but a little unsatisfying given the very small observed difference in SHP-1 binding. If the authors have additional thoughts, I would be interested to hear them.

This reviewer raised an excellent point. We agree that the Valine, Leucine or Isoleucine at the pY+1 position of ITIM did not product an obvious increase in SHP1 recruitment over Alanine at the same position. To further address this concern, we have conducted new functional experiment measuring how the identity of the pY+1 residue affect the ability of PD-1 to inhibit IL-2 production from Jurkat cells. Our result showed that medium sized residues, such as Alanine, Valine, Leucine and Isoleucine, increased the PD-1 potency to a similar extent over the WT PD-1. Therefore, we have removed the questionable discussion about the “sub-maximal SHP1 affinity” in the revised manuscript. That being said, both SHP1 recruitment and IL2 suppression showed a bell shaped dependence on the side chain volume of pY+1 residue, as supported by our new structural modeling data mentioned above. We have make this point clear in the revised manuscript.

(b) The authors note that PD-1 is the only ITIM with a glycine in the Y+1 position. Are there other receptors that function primarily through SHP-2, and how might they achieve this specificity?

Among the several receptors that we tested, PD-1 is the only receptor that exhibited no recruitment of SHP1. The lack of SHP1 recruitment is also true for murine PD-1, which has an acidic glutamate residue at Y+1 position. In addition, earlier work reported that PECAM1 also selectively recruits SHP2, but not SHP1. We have noted that PECAM1 contain a threonine (polar) at the pY+1 position of their ITIMs. Thus, their inability to recruit SHP1 is consistent with our model that a nonpolar residue at Y+1 position is required for strong SHP1 recruitment. We have discussed these points in the revised manuscript.

Figure 9 b Val not Vla, Figure 3a – a legend for the color code may be nice (ie, 20-1000 nM)

We thank the reviewer for catching these, we have fixed the error in Figure 9B and provide the color code in Figure 3A in the revised manuscript.

Reviewer #3 (Significance (Required)):

Significance:

SHP-1 and SHP-2 play a critical role in regulating immune system function. In addition, the receptors recruiting these phosphatases (like PD-1) are important immunotherapy targets. Previously, the question of SHP-1/SHP-2 specificity has been primarily described for ITIM bearing receptors individually. Other studies have predicted consensus sequences for the tSH2 domains of SHP-1 or SHP-2, but not addressed the defining molecular characteristics of these consensus sites or how these could be combined on ITIM receptors to generate selectivity between these related phosphatases. This paper represents a significant step forward because it provides a unifying mechanism explaining how ITIM-bearing immune receptors specifically recruit SHP-1 or SHP-2. I expect this paper will be broadly interesting to biochemists, immunologists and cancer biologists.

Referee Cross-commenting

I generally think the other reviewers comments are reasonable and insightful. Together, they suggest no new experiments are necessary. As for the proposed title change, I prefer the authors title and find it to be justified given their data.

Reviewer #4 (Evidence, reproducibility and clarity (Required)):

In this manuscript, Xu and college performed an elaborate study to investigate the molecular basis of Shp1 and Shp2 discrimination by immune checkpoints PD-1 and BTLA. The paper is original, clear, and well written. I only have a few minor comments:

1. Please label the molecular weights to all the western blots/IPs results.

We have labeled the molecular weights to all the blots in the revised manuscript.

2. Please add scale bars to all the microscopy pictures.

We have added scale bars to all the microscopy images in the revised manuscript.

3. For the SPR data, please add the fitting curves.

We thank the reviewer for the suggestion. However, we did not use the fitting curve to calculate the Kd, instead, we plotted the maximum response as a function of concentration to determine the Kd. This is another well accepted method for Kd calculation. In fact, some of the SPR curves fit poorly with the existing algorithm. Thus, showing the fitting curves might distract the readers.

Reviewer #4 (Significance (Required)):

The strength of this paper relies on the details they dissected by using a series of mutagenesis screening experiments, which should be interesting to cell biologists and cancer immunologists.

Referee Cross-commenting

I think the other reviewer's comments are insightful and constructive, the suggested experiments are necessary and will improve the paper.

We thank this reviewer for the positive comments!

Author details

1. Xiaozheng Xu

   Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, United States

   Contribution

   designed the project; generated plasmids, proteins and cell lines; conducted the co-IP experiments and IL-2 assays; initiated the collaboration with Qixu Cai on structural modeling and simulations; drafted, revised and finalized the manuscript

   Contributed equally with

   Takeya Masubuchi

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-6888-4285

2. Takeya Masubuchi

   Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, United States

   Contribution

   designed the project; generated plasmids, proteins and cell lines; conducted the cell-SLB assays, SPR experiments, and single molecule imaging; sequence queries of ITIM/ITSM containing receptors, wrote the customized code for single molecule imaging analyses; drafted, revised and finalized the manuscript

   Contributed equally with

   Xiaozheng Xu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-6822-3049

3. Qixu Cai

   Division of Life Science, State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong, China

   Contribution

   conducted the structural modeling and simulations

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-4525-4261

4. Yunlong Zhao

   Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, United States

   Contribution

   generated plasmids, proteins and cell lines

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-7392-4824

5. Enfu Hui

   Section of Cell & Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, United States

   Contribution

   conceived and supervised the project; drafted, revised and finalized the manuscript; obtained the funding

   For correspondence

   enfuhui@ucsd.edu

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-7876-2783

• 2,788

  Page views

• 490

  Downloads

• 5

  Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.